Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
9
×
life sciences
national blog main
national top stories
new york blog main
gene therapy
new york top stories
san francisco blog main
biotech
deals
hemophilia
san francisco top stories
clinical trials
national
san diego blog main
san diego top stories
spark therapeutics
alnylam pharmaceuticals
boston
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
raleigh-durham blog main
raleigh-durham top stories
sangamo therapeutics
seattle blog main
seattle top stories
texas blog main
texas top stories
vc
wisconsin blog main
wisconsin top stories
biomarin pharmaceutical
bluebird bio
car-t
celgene
What
gene
9
×
therapy
9
×
bio
medicine
roundup
approval
aren’t
cutting
deal
drug
edge
fda
help
long
market
moves
past
patients
race
rna
science
advanced
age
allergan
alnylam’s
becker
betting
bff
bigger
biggest
billion
billions
biopharma
blessing
bosley
car
ceo
check
clinical
close
Language
unset
Current search:
gene
×
therapy
×
" boston top stories "
×
@xconomy.com
4 years ago
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
@xconomy.com
4 years ago
Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More
@xconomy.com
4 years ago
With Data, Pfizer/Sangamo Step Forward in Hemophilia Gene Therapy Race
@xconomy.com
4 years ago
Encoded Nabs $104M, Illumina’s Help, to Push Gene Therapy’s Limits
@xconomy.com
5 years ago
Bio Roundup: EASL Does It, Alnylam’s BFF, Gene Therapy Deals & More
@xconomy.com
5 years ago
With $100M MeiraGTx Deal, J&J Signals Bigger Move Into Gene Therapy
@xconomy.com
5 years ago
Editas CEO Katrine Bosley to Depart on Cusp of CRISPR Clinical Trial
@xconomy.com
5 years ago
Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More
@xconomy.com
5 years ago
CAR-T’s Launch, Payers vs. Gene Therapy & Photos From “What’s Hot”